Atlas.
Sign inStart free trial
FATENASDAQ · US

FATE THERAPEUTICS INC

Technology · Biological Products, (No Diagnostic Substances)

TechnologyBiological Products, (No Diagnostic Substances)
CEO
Bob Valamehr
Founded
—
IPO Date
—
HQ
San Diego, CA, United States
Exchange
NASDAQ
Employees
n.a.

Share Price Performance

$3.02 ▲ 206.2%
Last (1 Jul 2026) · $3
Period High · $3.02
Period Low · $0.99
52W: $0.92 – $3.02

Key Metrics

Share Price
$3.02
+11.8% today
Market Cap
$348M
P / E
—
EV / Revenue
45.4x
Revenue Growth
-51.2%
year-on-year
Gross Margin
—
Enterprise Value
$302M
52W High
$3.02
52W Low
$0.92
Avg Volume
3.5M
daily

Sources: SEC filings · Market data as of Jul 6, 2026

Shareholders' Structure
13 known institutional holders·$26M total on record·2026-Q1
BlackRock, Inc.
8.7%·$12M
Renaissance Technologies LLC
2.6%·$4M
Geode Capital Management, LLC
2.2%·$3M
State Street Corp
2.0%·$3M
Goldman Sachs Group Inc
1.2%·$2M
Dimensional Fund Advisors LP
0.8%·$1M
Northern Trust Corp
0.7%·$974,305
Invesco Ltd.
0.3%·$451,063
Bank Of America Corp
0.2%·$226,276
Price T Rowe Associates Inc
0.1%·$92
Fmr LLC
0.0%·$57,108
Jpmorgan Chase & Co
0.0%·$50,723
Point72 Asset Management, L.P.
0.0%·$51,743
Free Float
81.2%

Sources: SEC filings

Notes: % shown as share of total shares outstanding · Free float = shares outstanding minus all known 13F institutional holdings

What Atlas covers for FATE THERAPEUTICS INC
OverviewFATE THERAPEUTICS INC share price history (10 years), key market statistics, and institutional shareholder structure from SEC 13F-HR filings.Business ModelHow FATE THERAPEUTICS INC generates revenue — product and service segments, geographic breakdown, key operating metrics, and 10-year business evolution sourced from SEC filings.FinancialsFATE THERAPEUTICS INC's complete financial history — 10 years of annual revenue, gross margins, operating income, net income, EPS, and free cash flow from SEC filings, plus 12 quarters of quarterly results.Management QualityFATE THERAPEUTICS INC executive team profiles, insider buying and selling from SEC Form 4, earnings call transcripts, and a track record of guidance delivery vs actual results.Risk FactorsFATE THERAPEUTICS INC's annual risk disclosures from SEC filings — full text, 5-year evolution showing how risks have shifted, and year-on-year delta highlighting new and removed risks.NewsAI-synthesised news digest for FATE THERAPEUTICS INC, updated regularly with key developments, earnings updates, product announcements, and material company events.SentimentInvestor sentiment for FATE THERAPEUTICS INC aggregated from X.com, Reddit, and Hacker News — discussion themes, Bull and Bear signals, and community analysis.Valuation & PeersFATE THERAPEUTICS INC valuation multiples — P/E, EV/Revenue, EV/EBITDA — compared against a curated set of industry peers using live data from SEC filings. Custom peer selection available.DCF BuilderBuild a discounted cash flow model for FATE THERAPEUTICS INC with 10 years of pre-filled revenue, margins, and cash flow data from SEC filings. Adjust growth rates, WACC, and terminal assumptions.Atlas AnalysisAtlas AI research synthesis for FATE THERAPEUTICS INC — business model, financial health, management quality, risk profile, and institutional ownership, grounded exclusively in SEC filings.

Unlock the full analysis

9-tab institutional research sourced directly from SEC filings. No tips, no scores — the same process professional investors use.

7-day free trial · Plus & Pro · No charge during trial